FDA official says "no evidence" of Cox-2 problem

An FDA deputy commissioner said the agency has not yet decided if the problems that led to withdrawal of Merck's Vioxx means the agency also should consider whether similar drugs are a concern. "We don't have any definitive evidence" the heart-risk problem that affected the Vioxx arthritis drug also is involved in other drugs in the Cox-2 class, Janet Woodcock said at a conference of arthritis specialists.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director of Product Planning Development; Market Planning, Innovation
Blue Cross Blue Shield of Massachusetts
Quincy , MA
Director, Payer Marketing
Avalere Health
Washington, DC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX